Evgen Pharma PLC Result of General Meeting & Total Voting Rights (0583R)

TIDMEVG

RNS Number : 0583R

Evgen Pharma PLC

03 March 2021

Evgen Pharma plc

("Evgen" or "the Company")

Result of General Meeting

and

Total Voting Rights

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders on a poll.

The numbers of votes cast for and against each of the Resolutions are detailed below:

 
 Resolution   Votes for    % of votes cast   Votes against   % of votes cast   Total votes cast   Votes withheld 
 1            34,363,025   99.91%            30,000          0.09%             34,393,025         108,375 
             -----------  ----------------  --------------  ----------------  -----------------  --------------- 
 2            34,324,025   99.82%            61,695          0.18%             34,385,720         115,680 
             -----------  ----------------  --------------  ----------------  -----------------  --------------- 
 

It is expected that the Admission of the Placing Shares and the Open Offer shares will become effective at 8:00 a.m. on 4 March 2021.

Following Admission, the Company will have in issue 274,888,117 Ordinary Shares, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the Placing and Open Offer announcement issued on 2 February 2021.

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                          via Walbrook 
-------------------------------------- 
 Dr H uw Jones CEO 
-------------------------------------- 
 Richard Moulson, CFO 
-------------------------------------- 
 
 finnCap www.finncap.com                                         [phone] 
-------------------------------------- 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
-------------------------------------- 
 Alice Lane, Manasa Patil (ECM) 
-------------------------------------- 
 
 Walbrook PR                             [phone] or [e-mail] 
-------------------------------------- 
                                                [phone] / [phone] 
 Paul McManus / Anna Dunphy                                                       001 
-------------------------------------- 
 

About Evgen Pharma plc

Evgen Pharma is a clinical stage company developing sulforaphane based medicines for the treatment of multiple diseases The Company's core technology is Sulforadex (R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. Our lead product, SFX-01, has demonstrated efficacy in a Phase II trial for advanced metastatic breast cancer. It has been used to treat over 150 patients in clinical trials and is well-tolerated with predominately mild side-effects.

Evgen shares are traded on the AIM market of the London Stock under the ticker symbol EVG.

For further information, please visit: www.evgen.com

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 
 1.   Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated 
       with them ('PCA') 
===  ================================================================================================ 
 a)   Name                                         Huw Jones 
===  ============================================  ================================================== 
 2.   Reason for notification 
===  ================================================================================================ 
 b)   Position / status                            CEO 
===  ============================================  ================================================== 
 c)   Initial notification / amendment             Initial Notification 
===  ============================================  ================================================== 
 3.   Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
===  ================================================================================================ 
 b)   Name                                         Evgen Pharma plc 
===  ============================================  ================================================== 
 c)   LEI                                          213800NO3E6TSTQO8K20 
===  ============================================  ================================================== 
 4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
===  ================================================================================================ 
 a)   Description of the financial instrument       ordinary shares of 0.25p each 
 
       Identification code 
                                                     GB00BSVYN304 
===  ============================================  ================================================== 
 b)   Nature of the transaction                     Acquisition of shares pursuant to the Placing 
===  ============================================  ================================================== 
 c)   Price(s) and volume(s)                          Price(s)    Volume(s) 
                                                       GBP0.08     62,500 
                                                                  ---------- 
===  ============================================  ================================================== 
 d)   Aggregated information                        As above 
       Aggregated volume Price 
===  ============================================  ================================================== 
 e)   Date of the transaction                       3 March 2021 
===  ============================================  ================================================== 
 f)   Place of the transaction                      London Stock Exchange, AIM Market (XLON) 
===  ============================================  ================================================== 
 
 
 1.   Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated 
       with them ('PCA') 
===  ================================================================================================ 
 a)   Name                                         Sue Foden 
===  ============================================  ================================================== 
 2.   Reason for notification 
===  ================================================================================================ 
 b)   Position / status                            Non-Executive Director 
===  ============================================  ================================================== 
 c)   Initial notification / amendment             Initial Notification 
===  ============================================  ================================================== 
 3.   Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
===  ================================================================================================ 
 b)   Name                                         Evgen Pharma plc 
===  ============================================  ================================================== 
 c)   LEI                                          213800NO3E6TSTQO8K20 
===  ============================================  ================================================== 
 4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
===  ================================================================================================ 
 a)   Description of the financial instrument       Ordinary Shares of 0.25p each 
 
       Identification code 
                                                     GB00BSVYN304 
===  ============================================  ================================================== 
 b)   Nature of the transaction                     Acquisition of shares pursuant to the Placing 
===  ============================================  ================================================== 
 c)   Price(s) and volume(s)                          Price(s)    Volume(s) 
                                                       GBP0.08     125,000 
                                                                  ---------- 
===  ============================================  ================================================== 
 d)   Aggregated information                        As above 
       Aggregated volume Price 
===  ============================================  ================================================== 
 e)   Date of the transaction                       3 March 2021 
===  ============================================  ================================================== 
 f)   Place of the transaction                      London Stock Exchange, AIM Market (XLON) 
===  ============================================  ================================================== 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMSSAFEDEFSESD

(END) Dow Jones Newswires

March 03, 2021 07:10 ET (12:10 GMT)